© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.

Introduction

Spring 2018

1

© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.

1. We uniquely deliver meaningful and actionable health insightsacross many diseases, conditions and markets

2. These insights are derived from precise, proprietary and simultaneous measurement of 5000 proteins; every sample, every time

3. Our protein-based insights empower users to continuously optimize their personal health and wellness

2

Leading the future of healthcare

Healthcare today

3

• Focused on “sick” care• Major players try to lead, but are

fragmented• Includes payers, providers,

employers, Medicaid and Medicare, biopharma, and others

• Pay-for-service: Process and history more important than nimble response to new data

• Data types are fragmented, “noisy”

The future of healthcare

4

• Data-driven insights• Biology-based rational actions• “Root cause” analytics and

interventions• “Non-noisy” data predominates• Accessible

• Focused on personalized preventionand cures

• Features greater consumer/patient choice and control over traditional players

• Pay for outcomes/value

Technology convergence is driving the future of human health

5

Advanced big data interpretationand delivery technologies

Advanced “omics”measurement technologies

Crowded field of genomic information companies are trying to drive future healthcare

6

Genomic information is not sufficient

7

"Deg

résd

es â

ges"

, Fra

nçoi

s Geo

rgin

, 18

26. S

ourc

e: W

ikim

edia

Basically the same genome

Which “omic” delivers data-driven, highly personalized insights into real-time health?

• The proteome reflects:– dynamic “real-time” biology– current health status (response to

diet, environment, drug treatment, genetic variations, etc.)

• The genome is:– a static measurement of

potential future risk– basically the same throughout

life (“one and done”)

8

• Colored lines: Groups of protein changes in a single individual over 4 yrs.

• Black line: 900 proteins that remained stable

n=16

n=16

n=20

n=1

n=7

n=8

n=900

6/09 1/10 6/10 1/11 6/11 1/12 6/12 1/13 6/13

Conc

entr

atio

n

Time (4 years)

…other proteins change at various times

Most proteins stay constant…

Highly multiplexed proteomics-based health information will drive future healthcare

9

SomaLogic alone has the highly multiplexed proteomics technology needed to drive precision healthcare

• SomaLogic has developed the “SOMAscan®

assay,” a proprietary, scalable and CLIA-certified protein-measurement technology

• SOMAscan reproducibly measures 5,000 proteins (current version) across a wide concentration range in a single small sample volume

• SOMAscan can analyze thousands of samples a day, fully scalable

• The health-management insights derived from SOMAscan data put SomaLogic at the forefront of future healthcare information companies

10

“SomaLogic was started around a simple idea… We believed that medical diagnostics was not as useful for patients and healthcare as it had to be, and that

personalized medicine would depend on genomics and proteomics.”Larry Gold – 2015, Journal of Molecular Evolution

Access quality samples from many sources for many indications

• Pharmaceutical company collaborators– Disease knowledge, progression, recurrence– Drug efficacy, side effects– Large-scale learning collaborations, pharma-funded

• Academic collaborators– KOLs, Centers of Excellence in specific disease areas or

conditions• Major biobank collaborators

– Large cohorts with clinical outcome data that can yield insights across multiple disease areas

• 200K samples in queue for 2018, >1M by 2020

11

Sample & Clinical Dataacquisition

SomaLogic strategy

Analyze samples with SOMAscan assay

12

• SOMAscan analysis• 175,000 samples total through 2017• 200,000 samples in 2018• >1 million samples by 2020• Primary sample types are blood and

urine• 5,000 protein data points per sample,

all captured in proprietary Knowledge Base

Sample & Clinical Dataacquisition

SomaLogic strategy

Build proprietary massive “Knowledge Base” of protein and related data

13

SOMAscan Platform

“Knowledge Base”

• Information includes:• All SOMAscan-based protein

analyses and all related outcome data

• 1 billion protein measurements and related data by Q42018

• 5 billion by 2020• Continuous learning with new

samples (prospective and retrospective)

Sample & Clinical Dataacquisition

SomaLogic strategy

Deploy powerful computational tools to extract and validate insights from Knowledge Base

14

Extract Validated Insights

• Insights• Derived from proprietary computational algorithms• Actionable insights to guide subsequent health

decisions (medical, lifestyle, etc.)

SOMAscan Platform

“Knowledge Base”

Sample & Clinical Dataacquisition

SomaLogic strategy

Engage world-class collaborative “Test Beds” to establish clinical impact of insights

15

Apply to Health

Management (Test Beds)

• Health systems use insights to guide and assess interventions• Establish evidence of clinical impact for global marketing• Identify new product opportunities• First Test Bed: Leeds UK (NHS); four additional in negotiation

Extract Validated Insights

SOMAscan Platform

“Knowledge Base”

Sample & Clinical Dataacquisition

SomaLogic strategy

Commercialize validated products with clinical impact in large market segments

16

Commercialize in three sectors:• Health Systems• Employer Wellness Management• Consumer Health

Apply to Health

Management (Test Beds)

Extract Validated Insights

SOMAscan Platform

“Knowledge Base”

Sample & Clinical Dataacquisition

SomaLogic strategy

Expand Knowledge Base with continuous learning for finding new insights

17

• Linking SOMAscan data with EMR and person-reported outcomes yields new insights under continuous learning system

Continuouslearning

Commercialize in three sectors:• Health Systems• Employer Wellness Management• Consumer Health

Apply to Health

Management (Test Beds)

Extract Validated Insights

SOMAscan Platform

“Knowledge Base”

Sample & Clinical Dataacquisition

SomaLogic strategy

SOMAscan-based insights in the pipeline: Consumer/lifestyle

– Nutritional status– Lean muscle mass– Physical activity– Physical fitness– Response to glucose– Intra-abdominal fat– Lean muscle mass– Bone strength– Smoking impact– Smoking type– Alcohol impact

– Metabolic rate– Molecular BMI– Weight-loss predictions– Intermittent fasting benefit

prediction– Biological age– Diet response prediction– Social deprivation– Exceptional aging– Diabetes lifestyle intervention– Lifespan

18

We are developing a “proteomic mimic” for each of these phenotypes

SOMAscan-based insights in the pipeline: Medical/health systems

Death – probability

MI – probability

Stroke – probability

Heart failure – probability

Heart failure subphenotypeand prognosis

Hospital readmission after MI

PCSK9 drug response +/-HIV

Statin pharmacology

CV treatment benefit prediction

Drug toxicity – heart

Drug toxicity – muscle

Angiogram result

Statin response prediction

Diabetes status

Diabetes probability of developing

Diabetic complications

Bariatric surgery response

Liver fat

Liver inflammation

Liver fibrosis

NASH prognosis

Kidney function

Kidney prognosis

Cancer – early detection:

– Breast

– Colon

– Lung

– Prostate

– Rectum

– Melanoma

– Lymphoma

– Endometrium

– Pancreas

– Kidney

– Liver

Cancer – susceptibility:

– Breast

– Colon

– Lung

– Prostate

– Rectum

– Melanoma

– Lymphoma

– Endometrium

– Pancreas

– Kidney

– Liver

19

First product bundles: Cardiometabolic insights

20

Incident diabetes, cardiovascular risk, kidney prognosis, liver prognosis

Lean muscle mass, fitness, nutrition, metabolism, smoking, alcohol, insulin resistance

1. Relate intensity of intervention to risks2. Choose lifestyle changes most likely to

drive risk

Example: How do I prevent type 2 diabetes onset in a middle-aged overweight person with borderline HBA1c?

Using the cardiometabolic insight bundles to guide impactful health decisions

Define health decision(s) to be

enabled

Quantify relevant medical risks

using SOMAscan

Personalize with causal and/or

actionable insights

Guide intervention and monitor impact

21

Go-to-market steps and timing for cardiometabolic insight bundle

22

Additional insight bundles around other diseases and conditionsare in development throughout!

4Q17 1Q18 2Q18 3Q18 4Q18 2Q191Q19

• Cardiometabolicbundles identified as first products

• Samples acquired

• Engaged Leeds Test bed• Others in negotiation

• Prepare bundles for delivery (product development, ops, marketing)

• Deliver to Test bed(s), evaluate clinical impact

• Initiate formal commercialization of cardiometabolicinsight bundles

ABOUT SOMALOGIC

23

About• Founded in 2000 by Larry Gold, PhD, in Boulder, CO

• $600M total invested ($150M cash on balance sheet, $40M debt)

• $365M in equity

• $235M in non-dilutive funding

• 200+ employees

• >550 issued and pending patents

• World-class strategic partners:

24

Board of Directors and Advisors

25

• Larry Gold, Founder & ChairmanSynergen, NeXagen, NeXstar

• Charles M. LillisFormer Chairman and CEO, Media One Group, Inc.; Co-founder and Managing Partner, LoneTreeCapital

• Jessica MathewsFormer President, Carnegie Endowment forInternational Peace, PhD in Mol. Biology

• Terry L. RandallPresident-CEO, Heritage Capital, LLC

• Alister (Al) W. Reynolds, CEOFormer SVP of US Operations, Quest Diagnostics

• Takayuki ShiratsuchiOperating Officer, General Manager of Basic Research, Otsuka Pharmaceuticals

• Jun WangFounder and CEO of iCarbonX,former CEO and Chairman of BGI

• Sir Marc FeldmannEmeritus Professor, University of Oxford, UK

• Peter GanzProfessor, UCSF School of Medicine

• David LawrenceFormer Chairman & CEO, Kaiser Permanente

• Sir Simon LovestoneProfessor, University of Oxford

• Craig MundiePresident, Mundie & Associates; Former Chief Research and Strategy Officer, Microsoft

• Russell RayFormer Vice Chair and Managing Director of Healthcare Investment Banking, Stifel

• Elio RiboliDirector, School of Public Health, Imperial College, London

• John Stuelpnagel Executive Chairman, Ariosa Diagnostics; Chairman, 10x Genomics; Founder and former CEO and COO, Illumina

Board Advisors

Experienced leadership team

26

Alister (Al) W. ReynoldsChief Executive Officer

Matt NorkunasChief Financial Officer

Nebojsa JanjicChief Science Officer

Stephen WilliamsChief Medical Officer

Melody HarrisChief Legal Counsel

Alan WilliamsChief Development and Operations

Mark MessenbaughChief Corp Strategy & Development

Fintan SteeleChief Communications and Culture

© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.

1. We uniquely deliver meaningful and actionable health insightsacross many diseases, conditions and markets

2. These insights are derived from precise, proprietary and simultaneous measurement of 5000 proteins, every sample every time

3. Our protein-based insights empower users to continuously optimize their personal health and wellness

27

Leading the future of healthcare

© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc. 28

© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.

Backup slides: SOMAmers and SOMAscan

29

SOMAMERS AND SOMASCAN

30

Measuring the proteome: The challenge

31

From Baker et al. Genome Medicine 2012, 4:63

Mas

s spe

ctro

met

ry = ELISA (antibodies)

SOMAmer reagents:The heart of SomaLogic’s technology

32

• Slow Off-rate Modified Aptamers (SOMAmers) –A “next generation” of specific protein binding reagents

• Made from single-stranded DNA with “protein-like” side chains on specific bases

• Can be made to bind specifically to virtuallyany type of protein

Platelet-derived growth factor (dimer)

Nerve growth factor (dimer) Interleukin-6

The SOMAscan assay:Changing a protein measurement challenge

into a DNA measurement solution

33

• Combines thousands of different SOMAmer reagents to measure thousands of proteins in a small volume of biological sample

• Measures relative protein concentrations via DNA measurement of their binding SOMAmer partners

• Delivers unmatched specificity, sensitivity, dynamic range, reproducibility, scalability and speed

SOMAscan assay (1)

34

SOMAmers are pre-immobilized to beads

Proteins (sample) introduced into each well

Proteins bind to the SOMAmers

SOMAscan assay (2)

35

Proteins are biotinylated The photocleavable link is broken by exposure to

ultraviolet light

SOMAscan assay (3)

36

Non-specific complexes fall apart quickly

Specific complexes stay together (slow off-rate)

Second immobilization step on new beads

Unbound SOMAmers washed away

SOMAscan assay (4)

37

SOMAmers eluted off the complexes

# SOMAmers = # protein complexes

DNA SOMAmers hybridized to custom array,

Fluorescence = # SOMAmers

SOMAscan assay (5)

• Hybridization on custom Agilent arrays contributes to high dynamic range and excellent precision

• Every protein has its own standard curve

• 10 randomly placed spots averaged per protein

• A protein signal has been changed into a DNA signal

38